Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

ABBOTT LABORATORIES

(ABT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Abbott Laboratories Gets Expanded Indication for Infinity Deep Brain Stimulation System

share with twitter share with LinkedIn share with facebook
share via e-mail
01/24/2020 | 09:30am EST

By Michael Dabaie

Abbott Laboratories (ABT) said it received approval from the U.S. Food and Drug Administration for a new, expanded indication for the company's Infinity Deep Brain Stimulation system.

The company said the indication was expanded to include targeting of an area of the brain called the internal globus pallidus, or GPi. The GPi plays an integral role in the motor function and can be targeted with DBS to improve the symptoms of Parkinson's disease not adequately controlled by medication, the company said.

Abbott shares were up 1.4% in light premarket trading to $92.

Write to Michael Dabaie at michael.dabaie@wsj.com

Stocks mentioned in the article
ChangeLast1st jan.
ABBOTT LABORATORIES -1.14% 87.45 Delayed Quote.1.84%
DBS GROUP HOLDINGS LTD -0.08% 25.08 End-of-day quote.0.28%
GPI SPA -2.32% 7.58 Delayed Quote.-4.20%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ABBOTT LABORATORIES
02/21ABBOTT LABORATORIES : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIO..
AQ
02/21ABBOTT : Declares 385th Consecutive Quarterly Dividend
PR
02/18ABBOTT : Introduces Next-Generation Heart Rhythm Management Devices in Europe, F..
PR
02/11ABBOTT LABORATORIES : Change in Directors or Principal Officers (form 8-K)
AQ
02/05WALL STREET STOCK EXCHANGE : Tiffany is part of LVMH, Tesla gives some bad news,..
02/04ABBOTT LABORATORIES : Gets FDA Breakthrough Designation for Fully Implantable He..
DJ
02/04ABBOTT : 's In-Development Fully Implantable Heart Pump System Earns FDA's Break..
PR
02/03ABBOTT : Announces First-of-Its-Kind Trial to Assess New Therapy Option for Peop..
PR
01/31ABBOTT LABORATORIES : Tendyne device receives world's first ce mark for transcat..
AQ
01/30ABBOTT : 's Tendyne™ Device Receives World's First CE Mark for Transcathet..
PR
More news
Financials (USD)
Sales 2020 34 120 M
EBIT 2020 7 754 M
Net income 2020 4 460 M
Debt 2020 10 170 M
Yield 2020 1,60%
P/E ratio 2020 34,6x
P/E ratio 2021 28,2x
EV / Sales2020 4,82x
EV / Sales2021 4,37x
Capitalization 154 B
Chart ABBOTT LABORATORIES
Duration : Period :
Abbott Laboratories Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 99,28  $
Last Close Price 87,45  $
Spread / Highest target 25,8%
Spread / Average Target 13,5%
Spread / Lowest Target -10,8%
EPS Revisions
Managers
NameTitle
Miles D. White Chairman & Chief Executive Officer
Robert B. Ford President, Chief Operating Officer & Director
Brian Bernard Yoor Chief Financial Officer & Executive VP-Finance
Roxanne Schuh Austin Independent Director
Samuel C. Scott Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ABBOTT LABORATORIES1.84%154 212
MASIMO CORPORATION15.03%9 595
NOVOCURE LIMITED4.73%8 735
PENUMBRA, INC.16.95%6 708
ASAHI INTECC CO., LTD.0.33%6 386
GETINGE0.66%4 901